Skip to main content

Flagship Pioneering — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

70
Companies
$4.9B
Total invested
$73.8M
Avg. check
17
Industries
Biotechnology 20Health Care 13Therapeutics 12Medical 8Pharmaceutical 4Life Science 3+11 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 4970 of 70
Alltrna
August 2023

Alltrna is the creator of a tRNA platform that aims to decipher tRNA biology and pioneer therapies for disease treatment.

Biotechnology · Cambridge$109.0M Series B
Evelo Biosciences
July 2023

Evelo Biosciences is a biotechnology company that develops oral biologics for small intestinal axis with systemic therapeutic effects.

Biotechnology · Cambridge$25.5M Post Ipo Equity
Empress Therapeutics
June 2023

Empress Therapeutics is to generate transformative drug candidates that get to the clinic faster and cheaper.

Artificial Intelligence (AI) · Cambridge$50.0M Series Unknown
Metaphore Biotechnologies
May 2023

Metaphore Biotechnologies is a firm that uses biomimicry and machine learning to unlock the revolutionary therapeutic.

Biotechnology · Cambridge$50.0M Undisclosed
Ring Therapeutics
March 2023

Ring Therapeutics is a gene therapy company focused on discovering and developing programmable genetic medicines.

Biotechnology · Cambridge$86.5M Series C
Omega Therapeutics
February 2023

Omega Therapeutics offers a proprietary epigenomic programming platform.

Biotechnology · Cambridge$40.0M Post Ipo Equity
Montai Therapeutics
December 2022

Montai Health platform enables rapid and repeatable advancement of therapies across multiple diseases.

Health Care · Cambridge$50.0M Series A
Valo Health
October 2022

Valo Health is a technology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics.

Biotechnology · BostonSeries C
Axcella
October 2022

Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.

Biotechnology · Cambridge$34.2M Post Ipo Equity
Cellarity
October 2022

Cellarity is a therapeutics company that uses genomic technologies, data science, and AI to develop a new generation of therapies.

Biotechnology · Somerville$121.0M Series C
Codiak Biosciences
September 2022

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.

Biotechnology · San Francisco$20.0M Post Ipo Equity
ProFound Therapeutics
May 2022

ProFound Therapeutics is creating profound impacts on the understanding of biology and disease and the ability to create therapeutics.

Biotechnology · Cambridge$75.0M Series A
Vesalius Therapeutics
March 2022

Vesalius Therapeutics is focused on redefining the understanding and treatment of the diseases that drive ninety percent of human illness.

Biotechnology · Cambridge$75.0M Series A
Tarveda Therapeutics
September 2021

Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors.

Biotechnology · Watertown$6.0M Series Unknown
Repertoire Immune Medicines
April 2021

Repertoire Immune Medicines is a clinical stage biotechnology company.

Biotechnology · Cambridge$189.0M Series B
Rubius Therapeutics
March 2021

Rubius has developed the technology to grow, genetically engineer and mature long-circulating Red-Cell Therapeutics.

Biotechnology · Cambridge$200.0M Post Ipo Equity
Kaleido BioSciences
February 2021

Kaleido BioSciences is a company working to design and analyze the microbiome system and provide adaptive solutions.

Biotechnology · Bedford$60.4M Post Ipo Equity
Sigilon Therapeutics
December 2020

Sigilon Therapeutics is a biotech company that specializes in creating immune-privileged products for treating acute and chronic diseases.

Biotechnology · Cambridge$144.9M Post Ipo Equity
Cygnal Therapeutics
October 2019

Cygnal Therapeutics is a biotechnology company

Biotechnology · Cambridge$65.0M Series Unknown
KSQ Therapeutics
September 2018

KSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high-confidence drug development.

Biopharma · Cambridge$80.0M Series C
Sesen Bio
June 2018

Sesen Bio is focused on developing innovative protein-based therapeutics to improve human health and treat diseases.

Biotechnology · Cambridge$40.0M Post Ipo Equity
WikiCell Designs
September 2012

WikiCell Designs develops edible forms of packaging that enclose food or drinks in ways similar to how nature protects them.

Food and Beverage · Cambridge$10.0M Series A

Where Flagship Pioneering invests

Biotechnology20
Health Care13
Therapeutics12
Medical8
Pharmaceutical4
Life Science3

About Flagship Pioneering's portfolio

How many companies has Flagship Pioneering invested in?

Flagship Pioneering has invested in 70 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Flagship Pioneering invest in?

Flagship Pioneering's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 17 different industry categories.

What is Flagship Pioneering's largest investment?

Among tracked funding rounds, Rubius Therapeutics received $200.0M in a Post Ipo Equity round. Flagship Pioneering's total known invested capital is $4.9B.

What is the average investment size for Flagship Pioneering?

Flagship Pioneering's average investment size is $73.8M across its portfolio of 70 companies.

What are Flagship Pioneering's most recent investments?

Recent Flagship Pioneering portfolio additions include Alltrna, Evelo Biosciences, Empress Therapeutics, Metaphore Biotechnologies, Ring Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 70 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →